Loading
A phase 1/2 trial of atamparib escalation levels in non-small-cell lung cancer, run by Nerviano Medical Sciences (Shanghai) Ltd., now recruiting.
Atamparib in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07374419 by Nerviano Medical Sciences (Shanghai) Ltd., with 178 participants planned, started 2026-03-18 and due to reach its primary completion in 2028-07-31. Interventions recorded: atamparib escalation levels and atamparib RP2D.
Shares Nerviano Medical Sciences and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.